There is one clinical trial.
It is supposed to monitor hypertensive patients who are infected or have clinical manifestations of COVID-19 for 1 month after the onset of the disease. Three groups will be considered: 1. receiving ACE inhibitors 2. receiving ARBs 3. receiving DIR.
Description: BP one week before COVID-19 infection and 3 weeks follow-up after COVID-19 onsetMeasure: BP (hypertensive efficacy) Time: 4 weeks
Description: features of disease course: number of patients and duration of fever (above 37.2C), duration of cough (days), duration of throat pain (days), headache (days), nausea or vomiting (days), diarrhea (days), myalgia or arthalgia (days), and numder of patients who need hospital and intensive care unitMeasure: COVID-19 course Time: 3 weeks
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports